This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Structure Therapeutics Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small mol ...

Qiming has maintained a steady investment pace in 2023 and continued to evaluate and invest in exciting and disruptive areas. Additionally, Qiming strategically participated follow-on investments in high-quality portfolio companies. SHANGHAI, June 4, 2024 /PRNewswire/ -- The 2024 Forbes Midas List, a distinguished industry list of the world's best venture capital investors, has been unveiled. Nisa Leung, Managing Partner at Qiming Venture Partners, has become a Forbes Midas Lister for the sixth consecutive ...

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 8,000,000 American depositary shares (ADSs), each representing three ordinary shares. Structur ...

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 8,000,000 American depositary shares (ADSs), each representing three ordinary shares. Structur ...

Structure Therapeutics (NASDAQ:GPCR) stock is surging today, up 60% after the biotech company reported promising results of its mid-stage trials for its weight loss pills. Indeed, after 12 weeks, patients on the treatment lost an average of 6.2% of their weight, with one-third of patients losing more than 10% of their weight. This is comparable to Eli Lilly (NYSE:LLY) oforglipron pill at roughly the same point of its study. However, this came at the cost of vomiting, which almost 66% of Structure's patients ...

GSBR-1290 Overview - GSBR-1290 is an orally-available small molecule agonist of the GLP-1 receptor, targeting type 2 diabetes mellitus (T2DM) and obesity [1] - Designed as a biased GPCR agonist, selectively activating the G-protein signaling pathway [1] - Phase 2a study completed in participants with obesity or overweight and T2DM with BMI ≥27 [1] - Phase 2b study in obesity expected to start in Q4 2024, with Phase 2 development plan in T2DM to be determined in H2 2024 [1] - Next-generation combination GLP-1R candidates are also in development, including GIP, amylin, glucagon, and apelin oral small molecules [1] Clinical Trial Results - GSBR-1290 achieved a placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the capsule to tablet PK study at 12 weeks [3][7] - 67% of GSBR-1290-treated participants achieved ≥6% weight loss, and 33% achieved ≥10% weight loss at Week 12, compared to 0% for placebo [7] - The tablet formulation demonstrated comparable exposure to the capsule formulation, supporting dose proportional exposure and once-daily dosing [7] - GSBR-1290 showed generally favorable safety and tolerability, with low AE-related study discontinuations (5% in Phase 2a and 11% in PK study) [7] Future Development Plans - Phase 2b obesity study expected to begin in Q4 2024, using the tablet formulation and including approximately 300 participants [8] - IND submission to the FDA planned for Q3 2024 to support trials in chronic weight management [8] - The company anticipates using the tablet formulation for future studies, starting with the Phase 2b obesity study [10] Market and Industry Context - By 2030, the global prevalence of obesity is expected to reach 1 billion, highlighting the need for oral treatments that are scalable, stable, and cost-effective [6] - GSBR-1290 has the potential to become a best-in-class oral small molecule GLP-1RA and an ideal backbone for future combination therapeutics for obesity and related diseases [6] Company Background - Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral small molecule treatments for metabolic and cardiopulmonary conditions [11] - The company utilizes a structure-based drug discovery platform to develop GPCR-targeted therapies, aiming to overcome the limitations of traditional biologic and peptide therapies [11]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-41608 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 98-1480821 (Stat ...

Exhibit 99.1 Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights Topline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Plan to initiate dosing in first-in-human Phase 1 clinical trial of oral small molecule LPA1R Antagonist, LTSE-2578, for idiopathic pulmonary fibrosis in June 2024 SAN FRANCISCO – May 9, 2024 – Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage g ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-41608 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 98-1480821 (State of ...

Exhibit 99.1 Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Year-end cash balance of $467.3 million expected to fund operations and key clinical milestones through 2026 SAN FRANCISCO – March 8, 2 ...